FDA increases focus on postmarketing studies.
Goozner
Merrill
M
D000617:Aminoglycosides / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D000068258:Bevacizumab; D017327:Clinical Trials, Phase IV as Topic / Q000191:economics / Q000639:trends; D004345:Drug Industry / Q000191:economics / Q000639:trends; D000079982:Gemtuzumab; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D000077544:Panitumumab; D011358:Product Surveillance, Postmarketing / Q000191:economics / Q000592:standards / Q000639:trends; D014481:United States; D014486:United States Food and Drug Administration
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D000077544:Panitumumab; D000079982:Gemtuzumab